Jasper Therapeutics (NASDAQ:JSPR) Given “Market Outperform” Rating at JMP Securities

Jasper Therapeutics (NASDAQ:JSPR)‘s stock had its “market outperform” rating restated by investment analysts at JMP Securities in a report released on Monday,Benzinga reports. They presently have a $70.00 price objective on the stock. JMP Securities’ target price points to a potential upside of 263.26% from the company’s current price.

Several other brokerages have also recently commented on JSPR. Royal Bank of Canada restated an “outperform” rating and issued a $68.00 target price on shares of Jasper Therapeutics in a research report on Monday, December 23rd. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Jasper Therapeutics in a report on Monday, September 9th. BMO Capital Markets initiated coverage on Jasper Therapeutics in a report on Friday, December 6th. They set an “outperform” rating and a $63.00 price target for the company. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $65.00 price objective on shares of Jasper Therapeutics in a research note on Thursday, October 24th. Ten equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Jasper Therapeutics has an average rating of “Buy” and an average price target of $73.38.

Jasper Therapeutics Stock Performance

JSPR opened at $19.27 on Monday. Jasper Therapeutics has a 52-week low of $6.50 and a 52-week high of $31.01. The firm has a market cap of $289.07 million, a P/E ratio of -4.07 and a beta of 2.18. The business’s fifty day moving average is $22.07 and its 200-day moving average is $20.50.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Braidwell LP acquired a new position in Jasper Therapeutics in the 3rd quarter valued at approximately $9,091,000. Ally Bridge Group NY LLC boosted its position in Jasper Therapeutics by 82.7% during the third quarter. Ally Bridge Group NY LLC now owns 399,466 shares of the company’s stock valued at $7,514,000 after acquiring an additional 180,852 shares during the last quarter. Samsara BioCapital LLC raised its position in shares of Jasper Therapeutics by 11.4% in the 3rd quarter. Samsara BioCapital LLC now owns 584,642 shares of the company’s stock worth $10,997,000 after acquiring an additional 59,642 shares in the last quarter. FMR LLC acquired a new position in shares of Jasper Therapeutics in the 3rd quarter valued at about $722,000. Finally, Bank of New York Mellon Corp acquired a new stake in Jasper Therapeutics during the second quarter worth approximately $740,000. Institutional investors and hedge funds own 79.85% of the company’s stock.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.